logo
logo

Dualitas raises $65 million in Series A funding to advance its bispecific antibody pipeline in immune and inflammatory disease.

Sep 16, 2025•14 days ago

Amount Raised

$65 Million

Round Type

series a

San FranciscoBiotechnology

Description

Dualitas has successfully launched with a $65 million Series A funding round. The funds will be used to advance their innovative bispecific antibody pipeline. This investment aims to target immune and inflammatory diseases. Leading the round are prominent investors in the biotech space.

Company Information

Company

Dualitas Therapeutics

Location

681 Gateway Boulevard Suite 411

San Francisco, California, United States

About

Dualitas Therapeutics is a biotechnology company pioneering the future of bispecific antibody therapies for immune and inflammatory (I&I) diseases and beyond. Powered by our proprietary DualScreen™ discovery engine and a growing library of novel cell surface proximity engagers, our pipeline—including lead programs DTX-103 and DTX-102—has demonstrated compelling preclinical evidence supporting its potential to address important unmet patient needs. We offer partnering opportunities on the next generation of bispecific therapies in I&I diseases – and beyond.

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech